Health CarePharmaceuticals & Biotechnology
  • Price (JPY)2,233.00
  • Today's Change-3.00 / -0.13%
  • Shares traded788.40k
  • 1 Year change3.43%
  • Beta0.7640
Data delayed at least 20 minutes, as of Dec 19 2018 06:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of technologies for antibody drug creation, among others. It also involved in the contracting, retail and wholesale, and insurance agency businesses. The Biochemical segment manufactures and sells medical and industrial materials, mainly amino and nucleic acids, and healthcare products. This segment also designs and constructs facilities.

  • Revenue in JPY (TTM)346.03bn
  • Net income in JPY60.85bn
  • Incorporated1949
  • Employees7.53k
  • Location
    Kyowa Hakko Kirin Co LtdRoom 5485F, Otemachi Bldg., 1-6-1, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttp://www.kyowa-kirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Alfresa Holdings Corporation2.62tn39.44bn695.65bn11.90k16.181.3913.980.2654182.89182.8912,162.992,123.382.0017.684.34220,216,900.003.022.448.337.527.647.191.511.191.03--0.004222.082.001.7415.2011.3712.7410.90
Santen Pharmaceutical Co Ltd228.51bn34.37bn707.14bn3.81k20.622.3315.573.0984.2284.22559.95744.090.59032.983.0360,055,450.008.889.9410.3712.0260.9762.4915.0516.623.00349.790.096831.7412.9813.5762.2016.3722.465.39
Kyowa Hakko Kirin Co Ltd346.03bn60.85bn1.29tn7.53k20.131.8915.623.73111.05111.05631.501,180.490.48371.593.6345,941,850.008.514.229.464.8065.1062.2517.598.583.9536.750.00846.621.561.1940.8812.13-3.676.19
ONO PHARMACEUTICAL CO., LTD.284.79bn57.92bn1.40tn3.48k22.882.3520.634.92112.63112.63553.771,098.510.46812.523.6781,835,340.009.536.1010.716.7873.1374.5920.3617.482.88--0.001561.806.9612.89-9.8717.0231.442.13
Sumitomo Dainippon Pharma Co Ltd461.64bn35.98bn1.48tn6.27k41.023.0128.713.2090.5790.571,161.951,236.100.55451.643.8873,650,610.004.324.075.825.3775.9774.647.797.121.47--0.061927.9514.326.0770.6739.714.270.00
Data as of Dec 19 2018. Currency figures normalised to Kyowa Hakko Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

10.52%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 10 Oct 201817.82m3.09%
Nikko Asset Management Co., Ltd.as of 07 Dec 20187.52m1.31%
Daiwa Asset Management Co. Ltd.as of 30 Nov 20187.11m1.23%
The Vanguard Group, Inc.as of 31 Oct 20186.43m1.12%
Wellington Management Co. LLPas of 30 Nov 20186.30m1.09%
BlackRock Fund Advisorsas of 06 Dec 20184.34m0.75%
Norges Bank Investment Managementas of 31 Dec 20174.21m0.73%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 31 Oct 20183.68m0.64%
OppenheimerFunds, Inc.as of 31 Aug 20181.82m0.32%
Asset Management One Co., Ltd.as of 18 Sep 20181.42m0.25%
More ▼
Data from 31 Dec 2017 - 30 Sep 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.